About 1758 shares advanced, 1702 shares declined, and 145 shares were unchanged.
About 1758 shares advanced, 1702 shares declined, and 145 shares were unchanged. About 1758 shares advanced, 1702 shares declined, and 145 shares were unchanged. Moneycontrol Latest News Read More
About 1758 shares advanced, 1702 shares declined, and 145 shares were unchanged.
Dabur Q1 earnings: The company reported total revenue of Rs 3,130.47 crore in Q1FY24.
Dabur Q1 earnings: The company reported total revenue of Rs 3,130.47 crore in Q1FY24. Dabur Q1 earnings: The company reported total revenue of Rs 3,130.47 crore in Q1FY24. Moneycontrol Latest News Read More
Dabur Q1 earnings: The company reported total revenue of Rs 3,130.47 crore in Q1FY24.
Sequentially, the profit fell 13.35 percent from Rs 126.75 crore in Q4 FY23
Sequentially, the profit fell 13.35 percent from Rs 126.75 crore in Q4 FY23 Sequentially, the profit fell 13.35 percent from Rs 126.75 crore in Q4 FY23 Moneycontrol Latest News Read More
Sequentially, the profit fell 13.35 percent from Rs 126.75 crore in Q4 FY23
Biotechnology company Concord Biotech will be the first amongst them, planning to raise Rs 1,550.6 crore via maiden public issue. It is from the mainboard segment.
Biotechnology company Concord Biotech will be the first amongst them, planning to raise Rs 1,550.6 crore via maiden public issue. It is from the mainboard segment. Biotechnology company Concord Biotech will be the first amongst them, planning to raise Rs 1,550.6 crore via maiden public issue. It is from the mainboard segment. Moneycontrol Latest News Read More
Biotechnology company Concord Biotech will be the first amongst them, planning to raise Rs 1,550.6 crore via maiden public issue. It is from the mainboard segment.
The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing.
The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing. The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing. Moneycontrol Latest News Read More
The approval by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of Indomethacin suppositories of 50mg strength, the company said in a regulatory filing.
In today’s edition of Moneycontrol Pro Panorama: July PMI data shows strong economy, US credit rating downgrade no big deal, Indian start-ups enter global markets, peak rates pose investing challenge, and more
In today’s edition of Moneycontrol Pro Panorama: July PMI data shows strong economy, US credit rating downgrade no big deal, Indian start-ups enter global markets, peak rates pose investing challenge, and more In today’s edition of Moneycontrol Pro Panorama: July PMI data shows strong economy, US credit rating downgrade no big deal, Indian start-ups enter global markets, peak rates pose investing challenge, and more Moneycontrol Latest News Read More
In today’s edition of Moneycontrol Pro Panorama: July PMI data shows strong economy, US credit rating downgrade no big deal, Indian start-ups enter global markets, peak rates pose investing challenge, and more
The gross non-performing assets of the Mangalore-based bank declined to 3.68 percent as compared with 4.03 percent last year.
The gross non-performing assets of the Mangalore-based bank declined to 3.68 percent as compared with 4.03 percent last year. The gross non-performing assets of the Mangalore-based bank declined to 3.68 percent as compared with 4.03 percent last year. Moneycontrol Latest News Read More
The gross non-performing assets of the Mangalore-based bank declined to 3.68 percent as compared with 4.03 percent last year.
The SBI stock has given a return of 8.07 percent over the last six months. The stock has thus outperformed the benchmark Nifty Bank index by a small margin
The SBI stock has given a return of 8.07 percent over the last six months. The stock has thus outperformed the benchmark Nifty Bank index by a small margin The SBI stock has given a return of 8.07 percent over the last six months. The stock has thus outperformed the benchmark Nifty Bank index by a small margin Moneycontrol Latest News Read More
The SBI stock has given a return of 8.07 percent over the last six months. The stock has thus outperformed the benchmark Nifty Bank index by a small margin
Adani Enterprises Q1 result: The bottomline grew despite a 38 percent fall in the topline.
Adani Enterprises Q1 result: The bottomline grew despite a 38 percent fall in the topline. Adani Enterprises Q1 result: The bottomline grew despite a 38 percent fall in the topline. Moneycontrol Latest News Read More
Adani Enterprises Q1 result: The bottomline grew despite a 38 percent fall in the topline.
Credit card debts must be carefully managed for long-term financial security. Most credit card holders tend to make a few common mistakes that take them deeper into debt.
Credit card debts must be carefully managed for long-term financial security. Most credit card holders tend to make a few common mistakes that take them deeper into debt. Credit card debts must be carefully managed for long-term financial security. Most credit card holders tend to make a few common mistakes that take them deeper into debt. Moneycontrol Latest News Read More
Credit card debts must be carefully managed for long-term financial security. Most credit card holders tend to make a few common mistakes that take them deeper into debt.
English 
हिन्दी